Figure 5From: Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkersADORA3 clinical outcome evaluation. ADORA3 showed a significant (p = 0.05) poor outcome regarding metastasis formation in case of over-expression in both test (A) and validation (B) datasets we considered. Its role is connected to late stages of cancer development (> 2 years).Back to article page